Outcome at 8 years after breast-conserving surgery and radiation therapy for invasive breast cancer: Influence of margin status and systemic therapy on local recurrence

被引:415
作者
Park, CC
Mitsumori, M
Nixon, A
Recht, A
Connolly, J
Gelman, R
Silver, B
Hetelekidis, S
Abner, A
Harris, JR
Schnitt, SJ
机构
[1] Joint Ctr Radiat Therapy, Boston, MA 02215 USA
[2] Beth Israel Deaconess Med Ctr, Dept Radiat Oncol, Boston, MA USA
[3] Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA USA
[4] Brigham & Womens Hosp, Dept Radiat Oncol, Boston, MA 02115 USA
[5] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA
[6] Harvard Univ, Sch Med, Dana Farber Canc Inst, Div Biostat, Boston, MA 02115 USA
关键词
D O I
10.1200/JCO.2000.18.8.1668
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To examine the relationship between pathologic margin status and outcome at 8 years after breast-conserving surgery and radiation therapy, Patients and Methods: The study population comprised 533 patients with international Union Against Cancer/American Joint Committee on Cancer clinical stage I or II breast cancer who had assessable margins, who received at least 60 Gy to the primary tumor bed, and who had more than 8 years of potential follow-up. Each margin was scored (according to the presence of inversive or in situ disease that touched the inked surgical margin) as one of the following: negative, close, focally positive, or extensively positive. Outcome at 8 years was calculated using crude rates of first site of failure. A polychotomous logistic regression analysis was performed, Median follow-vp time was 127 months. Results: At 8 years, patients with close margins and those with negative margins both held a rate of local recurrence (LR) of: 7%, patients with extensively positive margins had an LR rate of 27%, whereas patients with focally positive margins had an intermediate rate of LR of 14%, In the polychotomous logistic regression model, margin status and the use of systemic therapy were the only two variables that had significant effects on the risk ratio of LR to remaining alive and free of disease, Among the 45 patients with focally positive margins who received systemic therapy, the crude LR rate was 7% at 8 years (95% confidence interval, 1% to 20%), Conclusion: Pathologic margin status and the use of adjuvant systemic therapy are the most important factors associated with LR among patients treated with breast-conserving surgery and radiation therapy. J Clin Oncol 88:1668-1675, (C) 2000 by American Society of Clinical Oncology.
引用
收藏
页码:1668 / 1675
页数:8
相关论文
共 30 条
[1]   LOCAL FAILURE AND MARGIN STATUS IN EARLY-STAGE BREAST-CARCINOMA TREATED WITH CONSERVATION SURGERY AND RADIATION-THERAPY [J].
ANSCHER, MS ;
JONES, P ;
PROSNITZ, LR ;
BLACKSTOCK, W ;
HEBERT, M ;
REDDICK, R ;
TUCKER, A ;
DODGE, R ;
LEIGHT, G ;
IGLEHART, JD ;
ROSENMAN, J .
ANNALS OF SURGERY, 1993, 218 (01) :22-28
[2]   MARGINS OF LUMPECTOMY FOR BREAST-CANCER [J].
CARTER, D .
HUMAN PATHOLOGY, 1986, 17 (04) :330-332
[3]   ANALYSIS OF LOCAL-REGIONAL RELAPSES IN PATIENTS WITH EARLY BREAST CANCERS TREATED BY EXCISION AND RADIOTHERAPY - EXPERIENCE OF THE INSTITUT GUSTAVE-ROUSSY [J].
CLARKE, DH ;
LE, MG ;
SARRAZIN, D ;
LACOMBE, MJ ;
FONTAINE, F ;
TRAVAGLI, JP ;
MAYLEVIN, F ;
CONTESSO, G ;
ARRIAGADA, R .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1985, 11 (01) :137-145
[4]   Breast conserving surgery for invasive breast cancer: Risk factors for ipsilateral breast tumor recurrences [J].
Dalberg, K ;
Mattsson, A ;
Rutqvist, LE ;
Johansson, U ;
Riddez, L ;
Sandelin, K .
BREAST CANCER RESEARCH AND TREATMENT, 1997, 43 (01) :73-86
[5]  
Dalberg K, 1998, CANCER-AM CANCER SOC, V82, P2204, DOI 10.1002/(SICI)1097-0142(19980601)82:11<2204::AID-CNCR15>3.3.CO
[6]  
2-J
[7]   Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: Eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil [J].
Fisher, B ;
Dignam, J ;
Mamounas, EP ;
Costantino, JP ;
Wickerham, DL ;
Redmond, C ;
Wolmark, N ;
Dimitrov, NV ;
Bowman, DM ;
Glass, AG ;
Atkins, JN ;
Abramson, N ;
Sutherland, CM ;
Aron, BS ;
Margolese, RG .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (07) :1982-1992
[8]   A RANDOMIZED CLINICAL-TRIAL EVALUATING TAMOXIFEN IN THE TREATMENT OF PATIENTS WITH NODE-NEGATIVE BREAST-CANCER WHO HAVE ESTROGEN-RECEPTOR POSITIVE TUMORS [J].
FISHER, B ;
COSTANTINO, J ;
REDMOND, C ;
POISSON, R ;
BOWMAN, D ;
COUTURE, J ;
DIMITROV, NV ;
WOLMARK, N ;
WICKERHAM, DL ;
FISHER, ER ;
MARGOLESE, R ;
ROBIDOUX, A ;
SHIBATA, H ;
TERZ, J ;
PATERSON, AHG ;
FELDMAN, MI ;
FARRAR, W ;
EVANS, J ;
LICKLEY, HL ;
KETNER, M .
NEW ENGLAND JOURNAL OF MEDICINE, 1989, 320 (08) :479-484
[9]   8-YEAR RESULTS OF A RANDOMIZED CLINICAL-TRIAL COMPARING TOTAL MASTECTOMY AND LUMPECTOMY WITH OR WITHOUT IRRADIATION IN THE TREATMENT OF BREAST-CANCER [J].
FISHER, B ;
REDMOND, C ;
POISSON, R ;
MARGOLESE, R ;
WOLMARK, N ;
WICKERHAM, L ;
FISHER, E ;
DEUTSCH, M ;
CAPLAN, R ;
PILCH, Y ;
GLASS, A ;
SHIBATA, H ;
LERNER, H ;
TERZ, J ;
SIDOROVICH, L .
NEW ENGLAND JOURNAL OF MEDICINE, 1989, 320 (13) :822-828
[10]  
FISHER B, 1993, P AM SOC CLIN ONCOL, V12, pA79